COCRYSTAL PHARMA, INC. Research and Development in Process
COCRYSTAL PHARMA, INC. (COCP) reported Research and Development in Process of $53.91 million for the 12-month period ending 2019-12-31, per its 10-K filed 2020-03-27.
Discontinued › Expense Statement › Operating Expenses
us-gaap:ResearchAndDevelopmentInProcess · last filed 2020-03-27
- COCRYSTAL PHARMA, INC. research and development in process for fiscal 2019 was $53.91M.
- COCRYSTAL PHARMA, INC. research and development in process for fiscal 2015 was $0.00, a 100.00% decline from fiscal 2014.
- COCRYSTAL PHARMA, INC. research and development in process for fiscal 2014 was $184.97M.
| Period end | Research and Development in Process 12 month |
|---|---|
| 2019-12-31 | $53.91M 10-K · filed 2020-03-27 |
| 2015-12-31 | $0.00 10-K · filed 2016-03-15 |
| 2014-12-31 | $184.97M 10-K · filed 2017-03-31 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ATOSSA THERAPEUTICS, INC. (ATOS) | United States | $0.021B | -0.52 |
| ARTELO BIOSCIENCES, INC. (ARTL) | United States | $0.023B | |
| Neuphoria Therapeutics Inc. (NEUP) | United States | $0.020B | -1.77 |
| Marker Therapeutics, Inc. (MRKR) | United States | $0.020B | -2.86 |
| Cellectar Biosciences, Inc. (CLRB) | United States | $0.020B | -1.03 |
| Shuttle Pharmaceuticals Holdings, Inc. (SHPH) | United States | $0.019B | -0.31 |
| TherapeuticsMD, Inc. (TXMD) | United States | $0.024B | -117.87 |
| NextCure, Inc. (NXTC) | United States | $0.024B | -0.15 |
| Rocket One Inc. (RKTO) | United States | $0.019B | |
| AYTU BIOPHARMA, INC (AYTU) | United States | $0.025B | -1.62 |